Fulcrum Therapeutics, Inc.FULCNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank29
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P29
Within normal range
vs 3Y Ago
-0.6x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
PeriodValue
Q4 2025-18.38%
Q3 2025-2.68%
Q2 20259.42%
Q1 20258.97%
Q4 202412.12%
Q3 2024-132.38%
Q2 2024332.95%
Q1 2024-9.18%
Q4 2023-1.10%
Q3 2023-10.20%
Q2 202313.81%
Q1 2023-22.44%
Q4 202229.36%
Q3 2022-1.89%
Q2 2022-23.79%
Q1 2022-1.13%
Q4 20213.17%
Q3 2021-26.67%
Q2 2021-9.83%
Q1 202118.16%
Q4 2020-340.19%
Q3 202068.10%
Q2 20207.12%
Q1 2020-238.24%
Q4 201965.47%
Q3 2019-7.81%
Q2 2019-22.00%
Q1 2019-54.57%
Q4 2018-55.41%
Q3 201823.80%
Q2 201818.47%
Q1 20180.00%